

Renal licences of commonly used anti-diabetes drugs

		CKD Stage 1 (>90)	CKD Stage 2 (60–90)	CKD Stage 3 (30–59)	CKD Stage 4 (15–29)	CKD Stage 5 (<15)
Other OADs	Metformin	No adjustment		2 g – 1 g/day*	Avoid use	
	Pioglitazone	No adjustment				
	Gliclazide	No adjustment		Dose reduction may be advised	Avoid use	
DPP-4i	Sitagliptin	No adjustment		50 mg/day**	25 mg/day	
	Alogliptin	No adjustment		12.5 mg/day†	6.25 mg/day	
	Linagliptin	No adjustment				
SGLT2i	Dapagliflozin	No adjustment‡		Avoid use		
	Canagliflozin	No adjustment‡		100 mg/day‡	Avoid use; eGFR <45 mL/min	
	Empagliflozin	No adjustment‡		10 mg/day‡	Avoid use; eGFR <45 mL/min	
GLP-1RA	Exenatide OW	No adjustment		Avoid use		
	Lixisenatide	No adjustment			Avoid use	
	Dulaglutide	No adjustment				Avoid use
	Liraglutide	No adjustment				Avoid use

■ Indicated
■ Restrictions apply
■ Contraindicated

*2 g with eGRF >45 mL/min and 1 g with eGFR 30–44 mL/min; **50 mg/day eGFR ≥30–50 mL/min; †12.5 mg/day eGFR ≥30–50 mL/min;

‡Additional licence precautions.

CKD, chronic kidney disease; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1RA, Glucagon-like peptide-1 receptor agonist; OAD, oral antidiabetic drug; OW, once-weekly; SGLT2i, Sodium-glucose co-transporter-2 inhibitor

Product SmPCs. Available at: www.medicines.org.uk/EMC/; ABCD-Renal Association guidelines <https://bjd-abcd.com/index.php/bjd/article/view/351>. Accessed August 2018